A multidisciplinary team approach to skull base chondrosarcomas.
OBJECTIVE
The authors review their experience with treating skull base chondrosarcomas, which are much rarer than skull base chordomas and differ from them in prognosis and treatment.


METHODS
Seventeen patients (12 male and five female patients) with histologically verified chondrosarcomas were followed up prospectively over a 12-year period. The mean age at presentation was 35.9 years. Most patients presented with cranial nerve palsies. Seven had undergone surgery prior to referral to the authors' unit. All underwent maximum surgical cytoreduction by the most direct surgical approach; only the two patients harboring the mesenchymal variant underwent radiotherapy.


CONCLUSIONS
One patient died of a pulmonary embolus; the patients harboring mesenchymal chondrosarcomas died at 20 and 36 months, respectively, after treatment. Of the remaining patients, 93% were alive 5 years postsurgery and had a projected 10-year survival rate of 84% (mean survival time 9.3 years). These data emphasize the very slow progression of this tumor compared with skull base chordoma.
Crockard
H A
HA
Department of Surgical Neurology, The National Hospital for Neurology and Neurosurgery, London, United Kingdom. A.Crockard@ion.ucl.ac.uk
Cheeseman
A
A
Steel
T
T
Revesz
T
T
Holton
J L
JL
Plowman
N
N
Singh
A
A
Crossman
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D024221:Antineoplastic Protocols; D001921:Brain / Q000000981:diagnostic imaging / Q000473:pathology; D002813:Chondrosarcoma / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D011859:Radiography; D019292:Skull Base Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery*; D015996:Survival Rate; D013997:Time Factors